Abbott has launched a clinical trial of its investigational Tendyne Transcatheter Mitral Valve Replacement (TMVR) device in the US to treat patients with mitral regurgitation (MR).
Designed for MR patients who need a minimally invasive replacement valve, Tendyne allows repositioning and complete retrieval to ensure precise placement during implantations.
This tri-leaflet, bioprosthetic valve eliminates the need for an open heart surgery. It comes in various sizes and conforms to a variety of anatomies, enabling easy use and better patient outcomes.
